These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R; Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192 [TBL] [Abstract][Full Text] [Related]
24. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254 [TBL] [Abstract][Full Text] [Related]
25. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. Carlsson SV; Holmberg E; Moss SM; Roobol MJ; Schröder FH; Tammela TL; Aus G; Auvinen AP; Hugosson J BJU Int; 2011 Jun; 107(12):1912-7. PubMed ID: 20950305 [TBL] [Abstract][Full Text] [Related]
26. Long-term biochemical recurrence rates after robot-assisted radical prostatectomy: analysis of a single-center series of patients with a minimum follow-up of 5 years. Suardi N; Ficarra V; Willemsen P; De Wil P; Gallina A; De Naeyer G; Schatteman P; Montorsi F; Carpentier P; Mottrie A Urology; 2012 Jan; 79(1):133-8. PubMed ID: 22088567 [TBL] [Abstract][Full Text] [Related]
27. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973 [TBL] [Abstract][Full Text] [Related]
29. The multiple imputation method: a case study involving secondary data analysis. Walani SR; Cleland CM Nurse Res; 2015 May; 22(5):13-9. PubMed ID: 25976532 [TBL] [Abstract][Full Text] [Related]
30. Cause of death during long-term follow-up for superficial esophageal adenocarcinoma. Kauppi J; Gockel I; Rantanen T; Hansen T; Ristimäki A; Lang H; Sihvo E; Räsänen J; Junginger T; Salo JA Ann Surg Oncol; 2013 Jul; 20(7):2428-33. PubMed ID: 23354564 [TBL] [Abstract][Full Text] [Related]
31. The impact of obesity on overall and cancer specific survival in men with prostate cancer. Davies BJ; Smaldone MC; Sadetsky N; Dall'era M; Carroll PR J Urol; 2009 Jul; 182(1):112-7; discussion 117. PubMed ID: 19447437 [TBL] [Abstract][Full Text] [Related]
32. 15-year cause specific and all-cause survival following brachytherapy for prostate cancer: negative impact of long-term hormonal therapy. Stone NN; Stock RG J Urol; 2014 Sep; 192(3):754-9. PubMed ID: 24698961 [TBL] [Abstract][Full Text] [Related]
33. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Culp SH; Schellhammer PF; Williams MB Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503 [TBL] [Abstract][Full Text] [Related]
34. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ; Brandt D; Schour L; Hill DR Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902 [TBL] [Abstract][Full Text] [Related]
35. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients. Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983 [TBL] [Abstract][Full Text] [Related]
36. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Popiolek M; Rider JR; Andrén O; Andersson SO; Holmberg L; Adami HO; Johansson JE Eur Urol; 2013 Mar; 63(3):428-35. PubMed ID: 23084329 [TBL] [Abstract][Full Text] [Related]
37. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL. Berthelet E; Pickles T; Lee KW; Liu M; Truong PT; Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):781-7. PubMed ID: 16199312 [TBL] [Abstract][Full Text] [Related]
38. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352 [TBL] [Abstract][Full Text] [Related]
39. Significance Tests and Estimates for van Ginkel JR Multivariate Behav Res; 2019; 54(4):514-529. PubMed ID: 30822143 [TBL] [Abstract][Full Text] [Related]